The IL-23/IL-17 pathway may be a novel therapeutic target for the treatment of 
psoriatic arthritis (PsA). The potential beneficial effect of Th-17A antagonism 
has been investigated by a randomized controlled trial in PsA patients with 
secukinumab, a fully human, high-affinity, monoclonal antibody in a cohort of 
patients with active PsA. Although this Phase II study presents bias that limits 
the ability of this drug to meet the primary and some secondary end points, the 
authors suggest that secukinumab may have biological effects and some clinical 
benefits in PsA patients. Further studies are required to demonstrate if the 
rationale to use drugs acting on the IL-23/IL-17 pathway is associated with 
relevant efficacy and safety in the treatment of PsA.